SunTrust analyst Peter Lawson lowered his price target on Epizyme to $20, saying that while the FDA hold on the tazemetostat trial should be brief, the 20% decline in the stock price afterhours justifies a more conservative target. In light of the hold, Lawson adds that he is also reducing his probability of success for tazemetostat to 60% from 65% and penetration to 75% from 85% in EZH2 mutant FL, while also reducing the probability of success in INI1-negative solid tumors to 60% from 85% and the penetration to 75% from 85%. The analyst keeps his Buy rating on Epizyme.